Ciphergen Forecasts Disappointing Q2 Revenues, Plans Cuts in Biosystems Business

Ciphergen Biosystems announced late Wednesday night that it expects a significant drop in revenues for the second quarter and that it plans to cut costs in its Biosystems division. The company’s stock plunged to a low of $3.95 per share on the heels of the news, a 40 percent drop in value from its Wednesday close of $7.32.

Ciphergen estimates revenues of $10 to $11 million for the quarter ending June 30, down from $14.3 million during the same period last year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.